Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McKesson Settles 2018 Price Fixing Suit With $141m Payment

Class Of Shareholders Had Alleged Financials ‘Premised On Illegal Activity’

Executive Summary

US distribution giant McKesson has reached a nine-figure settlement deal with shareholders to resolve a class action lawsuit alleging that it participated in a price-fixing and anticompetitive scheme for generic drugs with manufacturers and other wholesalers.

You may also be interested in...



Teva Agrees To $420m Securities Settlement For Alleged Price Fixing

Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.

McKesson shuffles pack

US-based wholesaler and retailer McKesson Corporation is to promote president and chief operating officer Brian Tyler to the role of chief executive officer following the retirement of John Hammergren.

US Supreme Court Reignites Claims Government Overcharged Millions For Generics

In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel